HIT Consultant March 25, 2025
What You Should Know:
– The pharmaceutical research and development (R&D) sector is experiencing a significant upswing, with projected returns on investment climbing to 5.9% in 2024, according to a new report by Deloitte.
– This surge, building on 2023’s 4.1%, is largely attributed to the success of GLP-1 therapies, showcasing the lucrative potential of addressing substantial unmet medical needs. However, this positive trend is juxtaposed with rising drug development costs and extended clinical trial timelines.
Report Background/Methodology
Deloitte’s 15th annual report, “Measuring the return from pharmaceutical innovation 2024” report provides insights into the biopharmaceutical industry’s performance, analyzing 20 leading global pharmaceutical companies using consistent methodology. This annual report, led by the Deloitte UK Centre for Health Solutions,...
Today's Sponsors
Today's Sponsor